Saw Elon Musk throwing out a pretty straightforward question on X the other day — basically asking why Americans can't actually afford decent healthcare. And Mark Cuban didn't just respond, he went full breakdown mode with a scathing analysis of how the whole system got so broken.

Cuban's take is worth paying attention to because he's not blaming politicians or whatever — he's calling out the real culprits: the pharmacy benefit managers (PBMs) and the contracts that lock companies into overpaying. Here's what he flagged as the main problems:

First, companies literally don't own their own data. When they sign with PBMs, they can't even see where their money's actually going. No transparency, no leverage to negotiate.

Second, PBMs decide which drugs employees get access to — not the companies paying the bills. So you end up with expensive meds pushed instead of cheaper alternatives that might work just as well.

Then there's the whole "specialty drugs" racket. Cuban called this out hard — these aren't actually special, they're just marked up to hell by PBMs, forcing employers to overpay even when identical options exist for a fraction of the cost.

The sickest employees end up subsidizing the system too. PBM rebate structures mean older and sicker workers get hit with higher deductibles and bigger co-pays. It's backwards.

Independent pharmacies are getting crushed because PBMs reimburse them below their actual costs, which kills competition and drives up prices for everyone. CEOs are basically handcuffed from negotiating better deals directly with manufacturers, and to top it off, these contracts come with NDAs so executives can't even talk about how bad the deals are.

But here's where it gets interesting — Cuban's actually building a solution. His company, Cost Plus Drugs, cuts out PBMs entirely and sells medications directly to consumers with full transparency. No hidden fees, no artificial markups. It's the kind of disruption the pharmaceutical industry needs.

Musk's question was simple, but Cuban's answer is basically a roadmap for how the system could actually change if someone's willing to challenge the existing model. Whether this direct-to-consumer approach scales remains to be seen, but at least someone's actually trying to fix it instead of just complaining.